The current status of checkpoint inhibitors in metastatic bladder cancer by Fahmy Ahmed, Omar Ahmed et al.
The current status of checkpoint inhibitors in metastatic bladder cancer 
ABSTRACT 
For many decades, no significant improvements could be achieved to prolong the survival in 
metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors 
(anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients 
with metastatic bladder cancer. We conducted a systematic review according to the PRISMA 
statement for data published on the clinical efficacy of checkpoint inhibitors in metastatic 
bladder cancer. Clinical efficacy of anti PD-L1 therapy was investigated in prospective trials 
in a total of 155 patients. Patients with positive expression for PD-L1 tended towards better 
overall response rates (ORR) compared to those with negative expression (34/76 vs 10/73, 45 
vs 14 %; p = 0.21). Among patients with PD-L1 positive tumors, those with non-visceral 
metastases exhibited significantly higher ORR compared to those with visceral metastases 
(82 vs 28 %; p = 0.001). For anti-CTLA4 therapy, there were no data retrievable on clinical 
efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder 
cancer are currently limited, the efficacy of these drugs might depend mainly on the 
metastatic volume and immune system integrity. Patients with PD-L1 positive tumors and 
non-visceral metastases seem to derive the highest benefit from therapy. 
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